HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.

Abstract
Increasing evidence supports the theory that tumor growth, homeostasis, and recurrence are dependent on a small subset of cells with stem cell properties, redefined cancer initiating cells (CICs) or cancer stem cells. Bone morphogenetic proteins (BMPs) are involved in cell-fate specification during embryogenesis, in the maintenance of developmental potency in adult stem cells and may contribute to sustain CIC populations in breast carcinoma. Using the mouse A17 cell model previously related to mesenchymal cancer stem cells and displaying properties of CICs, we investigated the role of BMPs in the control of breast cancer cell plasticity. We showed that an autocrine activation of BMP signaling is crucial for the maintenance of mesenchymal stem cell phenotype and tumorigenic potential of A17 cells. Pharmacological inhibition of BMP signaling cascade by Dorsomorphin resulted in the acquisition of epithelial-like traits by A17 cells, including expression of Citokeratin-18 and E-cadherin, through downregulation of Snail and Slug transcriptional factors and Cyclooxygenase-2 (COX2) expression, and in the loss of their stem-features and self-renewal ability. This phenotypic switch compromised A17 cell motility, invasiveness and in vitro tumor growth. These results reveal that BMPs are key molecules at the crossroad between stemness and cancer.
AuthorsChiara Garulli, Cristina Kalogris, Lucia Pietrella, Caterina Bartolacci, Cristina Andreani, Maurizio Falconi, Cristina Marchini, Augusto Amici
JournalCellular signalling (Cell Signal) Vol. 26 Issue 2 Pg. 352-62 (Feb 2014) ISSN: 1873-3913 [Electronic] England
PMID24280125 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Bmp4 protein, mouse
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins
  • Idb1 protein, mouse
  • Inhibitor of Differentiation Protein 1
  • Pyrazoles
  • Pyrimidines
  • dorsomorphin
  • Cyclooxygenase 2
  • Bmpr1a protein, mouse
  • Bmpr2 protein, mouse
  • Bone Morphogenetic Protein Receptors, Type I
  • Bone Morphogenetic Protein Receptors, Type II
Topics
  • Animals
  • Bone Morphogenetic Protein 4 (pharmacology)
  • Bone Morphogenetic Protein Receptors, Type I (metabolism)
  • Bone Morphogenetic Protein Receptors, Type II (metabolism)
  • Bone Morphogenetic Proteins (metabolism)
  • Breast Neoplasms (metabolism, pathology)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Survival (drug effects)
  • Cyclooxygenase 2 (genetics, metabolism)
  • Epithelial-Mesenchymal Transition (drug effects)
  • Female
  • Gene Expression Regulation (drug effects)
  • Humans
  • Inhibitor of Differentiation Protein 1 (metabolism)
  • Mice
  • Neoplastic Stem Cells (cytology, drug effects, metabolism)
  • Phenotype
  • Pyrazoles (chemistry, pharmacology)
  • Pyrimidines (chemistry, pharmacology)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: